GSK enters agreement to acquire Nuvalent, Inc. GlaxoSmithKline (GSK) has announced a $10.6 billion agreement to acquire Nuvalent, Inc., a Boston-based biopharmaceutical company specializing in oncology therapies. The deal, which includes three lung cancer assets, is designed to expand GSK’s presence in the field by addressing gaps in existing treatments for non-small cell lung cancer (NSCLC). The acquisition is expected to be accretive to GSK’s sales and core operating profit in 2027 and core earnings per share (EPS) in 2029, incorporating synergies and reprioritization of resources. The transaction encompasses two late-stage candidates for NSCLC: zidesamtinib (NVL-520), a ROS1 inhibitor, and neladalkib (NVL-655), an ALK inhibitor. Both drugs have received FDA Breakthrough Therapy and Orphan Drug Designations and are under review for potential 2026 approvals. Zidesamtinib has a target decision date of 18 September 2026, while neladalkib’s is set for 27 November 2026. If approved, these therapies could offer improved efficacy and tolerability compared to current standards, with the potential to address limitations in existing treatments. A third asset, NVL-330, is a HER2 inhibitor in phase I trials for HER2-altered NSCLC. The deal also includes Nuvalent’s preclinical pipeline, leveraging its precision medicine expertise and clinical insights from leading physician-scientists. GSK’s CEO, Luke Miels, emphasized the strategic value of the acquisition, stating that the deal aligns with the company’s focus on acquiring assets with validated targets that address unmet clinical needs. He highlighted the potential of zidesamtinib and neladalkib to provide significant new treatment options for patients with ROS1- and ALK-altered NSCLC, which primarily affect non-smoking adults aged 40-50.#gsk #nuvalent_inc #lukemiels #james_porter #iaslc_world_conference_on_lung_cancer
GSK to Acquire U.S. Cancer Drugmaker Nuvalent for $10.6 Billion GlaxoSmithKline (GSK), the U.K. pharmaceutical giant, has agreed to acquire U.S.-based oncology biotech Nuvalent for $10.6 billion in an all-cash deal. The transaction, which values Nuvalent at approximately $124 per share—a 40% premium to its last closing price—marks GSK’s largest acquisition in over a decade. The deal is expected to bolster GSK’s oncology pipeline and address declining revenue from its HIV medication, which will lose exclusivity in 2028. Nuvalent’s shares surged 39% in premarket trading, while GSK’s stock dipped 2.6% in London following the announcement. The acquisition includes Nuvalent’s two late-stage lung cancer treatments, which GSK described as having “blockbuster potential.” These therapies, zidesamtinib and neladalkib, are designed for specific genetic mutations in non-small cell lung cancer and are currently under FDA review. The deal also encompasses an early-stage medicine and Nuvalent’s preclinical portfolio. GSK CEO Luke Miels emphasized the strategic value of the acquisition, stating it would provide “immediate new sales growth opportunities” and offer significant treatment options for patients with two forms of lung cancer. Analysts at Barclays acknowledged the deal’s potential to accelerate GSK’s entry into the lung cancer space but questioned whether the two late-stage assets would achieve “mega blockbuster” status. They noted the upside for zidesamtinib and neladalkib was “capped” and highlighted the importance of the acquisition in offsetting revenue losses from the HIV drug’s patent expiration, which is projected to impact GSK starting mid-2028. The company reiterated that its 2026 financial guidance remains unchanged, with the acquisition expected to contribute to revenue growth beginning in 2027.#london #lung_cancer #gsk #nuvalent #ros1_positive_non_small_cell_lung_cancer
